Prior pharmacodynamic studies of adavosertib included pre and posttreatment tumor core or skin punch biopsies for inhibition of CDK1 phosphorylation or induction of γH2AX signifying enhanced DNA damage.26,27,30 In our preclinical studies, treatment with adavosertib led to increased expression of γH2AX in tumor tissue from treated mice compared to control animals. The gene discussed is CDK1; the disease is neoplasm.